Immulogic
This article was originally published in The Gray Sheet
Executive Summary
Exclusive licensing agreement with Heska Corp. focuses on the development and commercialization of Immulogic's recombinant allergen technology for diagnosis, immunotherapy and gene therapy for animals and humans. The company will receive license fees, milestone payments and royalties from Heska both for human and veterinary applications. The pact includes worldwide rights except in Japan where Immulogic has a non-exclusive license with Sankyo
Exclusive licensing agreement with Heska Corp. focuses on the development and commercialization of Immulogic's recombinant allergen technology for diagnosis, immunotherapy and gene therapy for animals and humans. The company will receive license fees, milestone payments and royalties from Heska both for human and veterinary applications. The pact includes worldwide rights except in Japan where Immulogic has a non-exclusive license with Sankyo. |